Patents by Inventor Frederick O. Cope

Frederick O. Cope has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190021608
    Abstract: Described herein are compositions and methods for diagnosing, imaging, and quantifying non-calcified atherosclerotic plaque. Embodiments of compositions described herein comprise mannosylated dextran compounds along with other carbohydrate molecules comprising, for example, a diagnostic agent and a diagnostic moiety. The compounds and methods embodied herein produce superior localization and results for imaging, anatomically locating, and quantifying non-calcified atherosclerotic plaque.
    Type: Application
    Filed: May 18, 2018
    Publication date: January 24, 2019
    Inventors: Frederick O. Cope, David Allen Ralph, Bonnie Chandler Abbruzzese
  • Publication number: 20190022259
    Abstract: The present application relates to compositions and methods for imaging and/or detecting tumors. In certain embodiments, the imaging and/or detection is targeted to tumor associated macrophages. In some embodiments, a mannosylated dextran construct is used to target and/or detect tumor associated macrophages. In some embodiments, the tumor may be one or more visceral tumors. In some embodiments, the detected and/or targeted tumor may be one or more metastatic tumors.
    Type: Application
    Filed: July 20, 2018
    Publication date: January 24, 2019
    Inventors: Frederick O. Cope, Bonnie Chandler Abbruzzese, David Allen Ralph, Allison Kissling
  • Publication number: 20180099048
    Abstract: Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for treating inflammatory diseases, such as parasitic diseases that result in cutaneous lesions. For example, and without limitation, such an parasitic disease can be leishmaniasis.
    Type: Application
    Filed: October 10, 2017
    Publication date: April 12, 2018
    Inventor: Frederick O. Cope
  • Publication number: 20180092998
    Abstract: A method of diagnosing an inflammasome-mediated disorder includes administering a pharmaceutical composition to a subject. The composition includes a carrier molecule having a detectable moiety attached thereto. The carrier molecule includes a non-toxic carbohydrate-based backbone. The method also includes after the administering step, detecting a presence of the detectable moiety at a predetermined location in the subject.
    Type: Application
    Filed: October 4, 2017
    Publication date: April 5, 2018
    Applicant: CARDINAL HEALTH, 414 LLC
    Inventor: Frederick O Cope
  • Publication number: 20180015187
    Abstract: Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 18, 2018
    Applicant: CARDINAL HEALTH 414, LLC
    Inventor: Frederick O. Cope
  • Publication number: 20160206763
    Abstract: Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 21, 2016
    Inventor: Frederick O. Cope
  • Publication number: 20150023876
    Abstract: A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 22, 2015
    Inventors: Frederick O. Cope, Michael S. Blue, Wendy L. Metz, Larry S. Schlesinger
  • Publication number: 20120270826
    Abstract: The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 25, 2012
    Inventors: Frederick O. Cope, Michael S. Blue
  • Publication number: 20100003674
    Abstract: MicroRNA genes are associated with regulatory elements of living cells of all species. The perturbations of the expression of these genes and their gene products in the cell or genomic structure or chromosomal architecture of a cell provide specific signatures on the condition of the cell and even the organism. Evaluation of miR gene expression can therefore be used to indicate the presence and state of specific cell types and/or their state of differentiation relative to their surrounding tissue. The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 7, 2010
    Inventors: Frederick O. Cope, Michael S. Blue
  • Patent number: 5547927
    Abstract: An enteral nutritional product has been formulated for persons who are currently undergoing radiation therapy and/or chemotherapy. The nutritional product has a protein system which includes a soy protein hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 fatty acids that is in the range of about 1.3:1 to 2.5:1.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: August 20, 1996
    Assignee: Abbott Laboratories
    Inventors: Frederick O. Cope, Normanella T. DeWille, Ernest W. Richards, Terrence B. Mazer, Bonnie C. Abbruzzese, Gregory A. Snowden, Nickki L. Parlet, Laura A. Pease
  • Patent number: 5514656
    Abstract: A method of providing enteral nutritional support to a person who is currently undergoing chemotherapy and/or radiation therapy involves including in the person's diet an enteral nutritional product having a protein system which includes a soy protein hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 fatty acids that is in the range of about 1.3:1 to 2.5:1.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: May 7, 1996
    Assignee: Abbott Laboratories
    Inventors: Frederick O. Cope, Normanella T. DeWille, Ernest W. Richards, Terrence B. Mazer, Bonnie C. Abbruzzese, Gregory A. Snowden, Nickki L. Parlet, Laura A. Pease
  • Patent number: 5480872
    Abstract: Enteral nutritional support for a person infected with human immunodeficiency virus is provided by including in the diet a nutritional product which contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: January 2, 1996
    Assignee: Abbott Laboratories
    Inventors: Frederick O. Cope, Normanella T. DeWille, Ernest W. Richards, Terrence B. Mazer, Bonnie C. Abbruzzese, Gregory A. Snowden, Michael A. Chandler
  • Patent number: 5403826
    Abstract: An enteral nutritional product for persons infected with human immunodeficiency virus contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: April 4, 1995
    Assignee: Abbott Laboratories
    Inventors: Frederick O. Cope, Normanella T. DeWille, Ernest W. Richards, Terrence B. Mazer, Bonnie C. Abbruzzese, Gregory A. Snowden, Michael A. Chandler
  • Patent number: 5330972
    Abstract: The apoptosis of CD4 cells in a person infected with the human immunodeficiency virus may be impeded by enterally feeding to the infected person a nutritional product which contains soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: July 19, 1994
    Assignee: Abbott Laboratories
    Inventor: Frederick O. Cope